Cartesian Therapeutics, Inc.
RNAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.00 | -0.02 | 0.18 |
| FCF Yield | -7.06% | -50.53% | -24.09% | -19.79% |
| EV / EBITDA | -3.49 | -0.15 | 1.70 | -44.94 |
| Quality | ||||
| ROIC | -10.58% | -33.28% | 9.63% | -4.86% |
| Gross Margin | 100.00% | 100.00% | 98.16% | 100.00% |
| Cash Conversion Ratio | 0.31 | 0.23 | -0.89 | 2.35 |
| Growth | ||||
| Revenue 3-Year CAGR | -29.44% | -32.64% | 88.28% | 133.57% |
| Free Cash Flow Growth | 36.21% | -56.45% | 46.59% | -280.44% |
| Safety | ||||
| Net Debt / EBITDA | 2.61 | 0.28 | -1.72 | 15.27 |
| Interest Coverage | 0.00 | -30.50 | 4.80 | -1.62 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 8.18 | 124.24 | -24.14 | 42.53 |